EAST RUTHERFORD, N.J., Nov. 1 /PRNewswire-FirstCall/ -- Cambrex Corporation commented today on the impact of the recent announcement regarding the status of Nabi Biopharmaceuticals’ product StaphVax(R).
(Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO )
“The recent announcement from Nabi Biopharmaceuticals does not impact our 2005 earnings guidance,” commented John R. Leone, President and Chief Executive Officer.
“We expect to provide 2006 guidance, as we normally do, during the fourth quarter 2005 earnings announcement after we have completed the evaluation of all of our prospects and opportunities within the Biopharma business and the potential impact of this news.”
Forward Looking Statement
This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under The Securities Exchange Act of 1934, including, without limitation, statements regarding expected performance, especially expectations with respect to sales, research and development expenditures, earnings per share, capital expenditures, acquisitions, divestitures, collaborations, or other expansion opportunities. These statements may be identified by the fact that words such as “expects,” “anticipates,” “intends,” “estimates,” “believes” or similar expressions are used in connection with any discussion of future financial and operating performance. The forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations including but not limited to, global economic trends, pharmaceutical outsourcing trends, competitive pricing or product developments, government legislation and/or regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, changes in foreign exchange rates, performance of minority investments, un-collectable receivables, loss on disposition of assets, cancellation or delays in renewal of contracts, and lack of suitable raw materials or packaging materials. For further details and a discussion of these and other risks and uncertainties, investors are cautioned to review the Cambrex Annual Report on Form 10-K, including the Forward-Looking Statement section therein, and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
About Cambrex Corporation
Cambrex is a global, diversified life sciences company dedicated to providing products and services to accelerate and improve the discovery and commercialization of human therapeutics. The Company employs approximately 1900 worldwide. For more information, please visit http://www.cambrex.com.
StaphVax(R) is a trademark of Nabi Biopharmaceuticals.
Photo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGOCambrex Corporation
CONTACT: Anne-Marie Hess, Director, Investor Relations & CorporateCommunications of Cambrex Corporation, +1-201-804-3062, orannemarie.hess@cambrex.com
Web site: http://www.cambrex.com/
Company News On-Call: http://www.prnewswire.com/comp/134219.html /
